Portfolio Companies

The Institute’s goal is to funnel advanced technology, including Defense and Space technologies, into currently existing commercial markets with immediate revenue generating capability. The proceeds of this recurring revenue will go in part towards funding more forward-looking technology development for emerging markets, such as the commercial space economy, which require longer development cycles. In this way, The Institute mitigates the risk of developing and deploying paradigm shifting technology by building a portfolio of companies which launch early iterations of the advanced technology to existing markets to fund longer term, further reaching development.

The current queue of companies in our pipeline is shown below. Each company in this pipeline is represented in terms of where it is in The Institute's Technology Commercialization Process: 1) technology triage, 2) maturation, 3) commercialization and 4) growth and exit phases with concept, design, prototype, patent protection, spin out Associate company formation, development of a market ready product, sales generation and company exit as major milestones of interest.

 

SpheroJet brings plasma thrusters for in-space propulsion to the commercial space market. The Institute’s PT-1 plasmoid thruster is a much-needed innovation in the satellite propulsion systems market, developed under the CTO of NASA’s Game Changing Technology Program at the Propulsion Systems Research and Development Lab at NASA Marshall Space Flight Center in Huntsville, AL.

The technical advantages of the PT-1, including flexible, inexpensive and environmentally safe fuel sources, increased fuel efficiency and the inclusion of fail-safe modes, will result in business advantages for satellite operators including dollars saved, equipment lifetimes extended and missions recovered. These advantages will also, in turn, enable a rapid establishment of nearby Earth Orbit infrastructure, as well as support various far reaching space-focused goals.

BioFreq is an agricultural processing company which applies space-aged solutions to the current technical bottlenecks of the hemp market. BioFreq’s proprietary platform uses sonic technology to purify crude oil into high quality pure spectrum CBD oil. 

Later stages of bioFreq's technology will be able to fractionate full spectrum CBD oil into its constituent chemical components of interest. An artificial intelligence platform is being integrated to optimize the purity and yield of the desired output with minimum expense. Our fractionation technology will allow additional market verticals to open up from the hemp space.

NucSense

 

NucSense utilizes proprietary neutron generator technology to produce elemental analysis fingerprints of target materials. This is achieved by bombarding a sample material with low energy neutrons. The nuclei of the atoms within the target sample absorb the neutrons and emit detectable gamma rays which can be read to determine the sample’s chemical composition. Our first use case is the elemental analysis of the dynamic oil content present within oil pipelines. There is significant variability in crude oil chemical composition as it passes from one point of custody to another via a pipeline. NucSense units can be installed cost-effectively along thousands of points along a pipeline to monitor the composition of oil in real time as it flows between points. Having access to this information allows downstream recipients of the oil to better prepare for the input they are about to receive into their facility.

GlioBlast leverages a similar proprietary neutron generator technology to the one used in NucSense, but with a twist. While NucSense emits low energy neutrons in all directions equally, GlioBlast creates a narrowly focused neutron beam that can be used for more precise applications of neutrons. This focused beam can then be used as a “neutron scalpel” to target chemically tagged glioblastoma tumors for destruction while leaving healthy cells unharmed. A similar procedure, Boron Capture Neutron Therapy, is already FDA approved for the treatment of glioblastoma tumors, but the need for the patient to be onsite at a nuclear reactor to obtain the neutrons required for treatment greatly limits the scalability of the procedure. GlioBlast will enable FDA approved Boron Capture Neutron Therapy using simply a table-top neutron generator, located in a hospital setting, to replace the current need for an off-site nuclear reactor.